Vanda Pharmaceuticals Inc. (VNDA)

Vanda Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	-	-	135.82	135.03	52.07
Short-Term Investments	-	-	252.44	331.83	380.74
Cash & Short-Term Investments	-	-	388.26	466.86	432.81
Cash Growth	-	-	-16.84%	7.87%	17.70%
Accounts Receivable	54.58	47.1	34.16	33.51	32.47
Inventory	12.94	10.83	11.34	12.57	9.17
Other Current Assets	-	-	9.17	17.73	12
Total Current Assets	67.51	57.93	432.95	519.29	478.3
Net Property, Plant & Equipment	11.27	10.55	9.14	10.97	12.39
Other Intangible Assets	117.09	114.1	121.37	18.57	20.08
Other Long-Term Assets	-	81.44	75	74.04	74.88
Total Assets	195.87	264.01	648.44	634.25	593.79
Accounts Payable	68.3	39.09	38.46	45.55	34.44
Other Current Liabilities	76.87	60.9	49.24	45.89	39.98
Total Current Liabilities	145.16	99.98	87.7	91.44	74.42
Long-Term Leases	7.07	8.09	7.01	8.81	10.06
Other Long-Term Liabilities	9.53	9.59	8.83	6.8	4.39
Total Long-Term Liabilities	16.6	17.68	15.83	15.61	14.45
Total Liabilities	161.76	117.66	103.53	107.05	88.86
Common Stock	0.06	0.06	0.06	0.06	0.06
Additional Paid-in Capital	721.26	712.71	700.27	686.24	669.22
Accumulated Other Comprehensive Income	0.63	0.07	-0.03	-1.19	-0.18
Retained Earnings	-394.77	-174.29	-155.39	-157.9	-164.18
Shareholders' Equity	327.19	538.55	544.91	527.2	504.93
Total Liabilities & Equity	488.95	656.2	648.44	634.25	593.79
Total Debt	7.07	8.09	7.01	8.81	10.06
Net Cash (Debt)	-7.07	-8.09	381.26	458.05	422.76
Net Cash Growth	-	-	-16.76%	8.35%	18.67%
Net Cash Per Share	-0.12	-0.14	6.62	8.04	7.43
Book Value	327.19	538.55	544.91	527.2	504.93
Book Value Per Share	5.55	9.26	9.47	9.25	8.87
Tangible Book Value	210.1	424.45	423.54	508.63	484.85
Tangible Book Value Per Share	3.57	7.30	7.36	8.93	8.52

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q